Antigenic variation during persistent infection has been extensively studied in three lentiviral systems: visna virus, caprine arthritis encephalitis virus, and equine infectious anemia virus (7, 12, 21-23, 25, 26, 31) . Animals persistently infected with these ungulate lentiviruses exhibit delayed neutralizing antibody responses against variant viruses which appear during the course of infection. Results derived from these lentiviral systems suggest that the host neutralizing antibody response selects neutralization escape mutants during the course of viral infection and that antigenic variation may contribute to persistent viral replication in chronically infected animals. Sequence changes responsible for resistance of these ungulate lentiviral variants to serum neutralization have not been defined. Furthermore, it is difficult to extrapolate the significance of these findings in ungulate systems to primate lentiviral systems because of the large phylogenetic distance.
Antibodies that neutralize human immunodeficiency virus type 1 (HIV-1) in infected people are largely directed against the envelope glycoprotein gpl20, and a number of linear and conformationally determined neutralization epitopes have been identified in this HIV-1-encoded product (for reviews, see references 28 and 35) . However, the relative importance of different target epitopes in HIV-1-infected people has not been clearly defined (27, 28, 35, 36) . Attempts to demonstrate the appearance of neutralization-resistant HIV-1 variants in infected humans have been largely hampered by lack of information on the genetic sequence of the initial infecting strain and by the presence of an already complex mix of genotypes in infected humans at the time that samples have been available for study. Nonetheless, several studies have indicated that neutralization-resistant HIV-1 variants emerge during the course of infection (1, 10, 38) .
Clear evidence for the emergence of neutralization escape variants has been presented for rhesus monkeys experimentally infected with molecularly cloned simian immunodeficiency virus (SIV) (4) . Sequential sera from infected animals showed much higher neutralizing antibody titers to the cloned virus used for infection than to cloned variants obtained 69 and 93 weeks after infection. As an important internal control for the demonstration of immune selection, rhesus monkeys were experimentally infected with cloned variant virus, and reciprocal neutralization tests were performed with variant-specific sera from these experimentally infected monkeys. Each cloned virus was neutralized best by its homologous antiserum. Only 20 amino acid changes in gpl20, mostly in discrete variable domains, were responsible for the resistance to cross-neutralization.
We now report that natural sequence variation in variable region 4 (V4) results in loss of recognition by at least one class of conformation-dependent antibodies that neutralize SIVmac infectivity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and T93 substituted env sequences (4, 33) . Four restriction enzyme sites V8-22 (variant 8-22) have been described previously (5, 6, 19, corresponding to nucleotides 6822 (HindlIl), 7045 (SpeI), 7758 30, 33) . p239SpSp5', p239SpE3', and pl-12SpE3' are plasmid (MroI) , and 8072 (ClaI) were used for the constructions. The numbering system is that of Regier and Desrosiers (33) . Vl is flanked by the HindIII and SpeI sites, and V4 and V5 are flanked by the MroI and ClaI sites (Fig. 1) .
MATERIALS AND METHODS
MAbs. The monoclonal antibodies (MAbs) Senv7.1, Senv 101.1, KK5, KK9, and KK17 used for these experiments were described previously (8, 17, 18) . Briefly, these MAbs were generated by using recombinant vaccinia virus expressing SIVmac251 gpl60 native antigen for immunization. BALB/c mice were inoculated intraperitoneally (17) or in the footpads (8) . Four weeks later, these mice were boosted intravenously (8) or intraperitoneally (17) . Mice were sacrificed, and the spleen cells were fused with the BALB/c myeloma cell line NSO. Hybridomas were screened by enzyme-linked immunosorbent assay and were cloned in soft agar before being inoculated into pristine-primed mice for production of ascitic fluid. The published properties of these MAbs are summarized in Table 1 (8, 11, 17, 18) . Antibodies of this type are made by rhesus monkeys as a natural response to SIV infection (24, 34 ).
The MAbs were tested for reactivity with a number of strains of SIVmac derived from cloned DNA. SIVmac239 was previously derived by animal passage of SIVmac251 (9, 19, 30, 33) . SIVmacl42 was independently isolated from another rhesus macaque of the same colony at the New England Regional Primate Research Center (6, 9) . The gpl2Os of the cloned SIVmac251 and SIVmac239 used for our studies differ at only 28 of 525 residues in gpl20 (95% amino acid identity) ( Fig. 1 ; Table 2 ). The gp120 of SIVmacl42 is more distantly related, with differences at 45 positions compared with gpl20 of SIVmac239 (91% amino acid identity) and 50 positions compared with gpl20 of SIVmac251 (90% amino acid identity) ( Fig. 1; Table 2 ). Variants 1-12 and 8-22 were derived from rhesus monkeys infected with cloned SIVmac239 (4, 5); these variants differ at only 20 residues in gpl20 compared with SIVmac239 ( Fig. 1; Table 2 ).
The gpl2Os of all of these cloned viruses reacted equally well by RIPA with sera from monkeys infected with SIVmac239 or SIVmac251 ( Fig. 2A) . The five MAbs all recognized SIVmac239 gpl20, but they did not react or reacted poorly with variants 1-12 and 8-22 ( Fig. 2A) . The gpl20 of SIVmacl42 was recognized somewhat by KK17, but it did not react significantly with the other four MAbs (Fig. 2A) . The results obtained with the five molecularly cloned viruses, summarized in well with sera from SIV-infected monkeys (Fig. 2B) . The pattern of reactivity with recombinant viruses strongly indicated that loss of recognition by the MAbs was associated with sequence changes in the V4/V5 region ( Fig. 2B and 3 ).
Individual amino acid changes responsible for loss of recognition. On the basis of the natural sequence variation in the V4 and V5 regions of the cloned viruses (Fig. 1) , seven site-specific mutations were created in SIVmac239. These mutations were designed to test which specific sequences in this region were responsible for loss of recognition by the five MAbs (Table 4 recognition by the MAbs by RIPA ( Fig. 4 ; Table 4 ). Changing 477Q to K in V5 did not significantly alter the recognition by the five MAbs in RIPA ( Fig. 4 ; Table 4 ).
To confirm and extend these findings, mutations were constructed in the gpl20 of variant [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] in an attempt to restore the reactivity. A single mutant virus was constructed in which the 409 position was restored from N to D and the KEQH sequence was reinserted at residues 422 to 425. The remainder of the Env glycoprotein is exactly that of variant 1-12. These five changes in variant 1-12 were able to completely restore the reactivity to all five MAbs (Fig. 5 ).
CD4 and MAb binding sites. To examine the effect of sCD4 binding on recognition of SIVmac239 envelope glycoprotein by the MAbs, 35S-labeled, NP-40-disrupted virus equivalent to 140 ng of p27 antigen was preincubated with sCD4 for 16 h. Two different sCD4 concentrations, 2.5 and 20 ,ug/ml, were used. Immunoprecipitation of gpl20 by MAbs KK5, KK9, and KK17 was not decreased detectably by preincubation with sCD4 under these conditions (Fig. 6A) In this report, we have shown that natural sequence variation in SIV V4 can result in escape from neutralization by at least one class of neutralizing antibodies. The neutralizing antibodies that were used were raised against native env antigen by immunization of mice with a vaccinia virus recombinant (8, 17, 18) . Most of the neutralizing antibodies that were identified from these studies, including the five used here, required native antigen for optimal recognition (8, 17, 18) . These findings suggest that neutralizing antibodies to SIVmac251 that recognize discontinuous or conformational epitopes may predominate over those that recognize linear epitopes, consistent with previous studies (15) . The five MAbs used in the present study are representative of a single, major, cross-competition group (8, 11, 14, 18) , and antibodies of this type have been shown to appear in rhesus monkeys as a natural response to SIV infection (24, 34) . Sequences in V4 appear to be uniformly important for recognition by this major class of SIVmac neutralizing antibody.
Several neutralization epitopes in the envelope of SIVmac have been previously reported. Some of the MAbs identified by Kent et peptide to block the neutralizing activity of polyclonal sera, demonstrated that amino acids 410 to 430 in V4 of gpl20 contain a neutralization epitope. The 409 and 420-425 determinants described in the current report are within or near this linear epitope described previously. Although extremely sensitive to sequence changes in V4, the five neutralizing antibodies used in this study do not react to any large extent with synthetic peptides, with E. coli-produced subfragments, or with denatured protein on Western blots, and thus they recognize conformational or discontinuous epitopes.
How do these results on the important role of V4 for recognition by one class of SIVmac neutralizing antibody relate to sequence requirements for neutralization of HIV-1? Unfortunately, little work has been done on the effects of natural sequence variation in HIV-1 V4 on recognition by conformation-sensitive MAbs that neutralize HIV (29) . Berkower et al. (3) have reported a major, conformation-dependent HIV-1 neutralization determinant mapping to a region of gpl20 (residues 342 to 511) that includes V4. It will be important to learn whether natural sequence variation in V4 of HIV-1 may similarly result in loss of recognition by some HIV-1 neutralizing antibodies.
The lack of reactivity of cloned SIVmacl42 and other recombinants suggests that sequence changes outside of V4 may also result in escape from recognition by these five MAbs.
Comparison of the sequences in V4 of SIVmacl42 with V4 sequences of clones that do react (SIVmac251, SIVmac239, and mutants 417A-4T, 417/418AN-4TK, and 415/416NT->SL) would predict no sequence changes in V4 of SIVmacl42 that should obviate recognition by the five MAbs ( Fig. 2; Table 4 ). Indeed, when the V4/V5 region of SIVmacl42 was substituted in SIVmac239, positive reactivity was observed with all five MAbs (7a). Similarly, exchange of Vl sequences did not alter the pattern of recognition. SIVmacl42 contains three amino acid changes at positions 327, 335, and 337 within the cysteine loop corresponding to V3 of HIV-1 (Fig. 2) , and these could possibly be responsible for the loss of recognition. Kent et al. (16a) have recently found that some SIVmac neutralization escape mutants generated in vitro to this class of antibody result from changes in V3, and Javaherian et al. (14) have presented evidence for conformationally determined SIV neutralizing activity dependent upon appropriate interaction of C-terminal sequences with V3.
The genetic approach that we have used is a powerful one for studying neutralizing antibodies that recognize complex conformational determinants. Because it utilizes the effects of natural sequence variation, it allows dissection of the mechanisms involved in escape from immune surveillance. Continued use of this approach should lead to a more detailed understanding of which variable domains are responsible for escape from different classes of neutralizing antibodies.
